Hunter Capital

Hunter Capital AB (publ) (“the Company” or “Hunter Capital”) today announces that it has entered into an agreement with CVI Investments Inc. (Heights Capital Management) (“Heights Capital”) to acquire 1,375,000 warrants, corresponding to 1,380,637 shares upon full exercise, in SynAct Pharma AB (publ) (“SynAct Pharma”).

In connection with this, Hunter Capital also undertakes to acquire 500,000 shares in SynAct Pharma from Heights Capital at a price of SEK 18.80 per share. After the transaction, Heights Capital will hold 250,000 shares in SynAct Pharma, without the right to convert additional shares under the warrant program launched in October 2023.

Through this acquisition, Hunter Capital strengthens its position as a shareholder in SynAct Pharma and contributes to increased stability as well as improved conditions for SynAct Pharma.

Hunter Capital has also entered into an agreement with SynAct Pharma under which the Company undertakes not to convert the warrants into shares. The warrants will expire in full on 13 October 2025, and no additional shares will be issued under this warrant program.

“Over the past six months, we have had a close and constructive collaboration with Heights Capital, which has led to this agreement. The acquisition of warrants and shares in SynAct Pharma strengthens our position as a long-term shareholder and provides better conditions for Synact Pharma.

We see this as a clear example of how strategic partnerships and carefully considered investments can contribute to stability and long-term value creation. Through our position, we aim to support SynAct Pharma’s continued development and growth while safeguarding the interests of all shareholders,” says Jacob Eriksson, Acting CEO of Hunter Capital.

For more information, please contact:
Jacob Eriksson, Acting CEO
E-mail: jacob.eriksson@huntercapital.se